louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06326801: Resistive Diaphragmatic Breathing Exercise With Pursed Lips Breathing Exercise in Sub-acute Stroke Patients
Official title: Effect of Resistive Diaphragmatic Breathing Exercise With Pursed Lips Breathing Exercise on Pulmonary Function, Trunk Control and Functional Capacity in Sub-acute Stroke Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke, Ischemic
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2024-03-22
Enrollment: 27
Sex: ALL
Minimum age (years): 40
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine whether resistive diaphragmatic breathing exercise with pursed lips breathing exercise improve pulmonary function in sub-acute ischemic stroke, To determine whether resistive diaphragmatic breathing exercise with pursed lips breathing exercise improve Trunk Control in sub-acute ischemic stroke, To determine whether resistive diaphragmatic breathing exercise with pursed lips breathing exercise improve Functional Capacity in sub-acute ischemic stroke


Eligibility criteria: Inclusion Criteria

* Age 40-65 years
* Onset of ischemic stroke in first two week
* First episode of unilateral stroke with hemiparesis during previous 12 months
* Patient with no serious cognitive deficits i-e mini-mental state examination (score \>22) ability to understand, perform and follow simple verbal instructions
* Functional ambulation category (FAC) \>3
* 6 min walk test distance should be \>200 m

Exclusion Criteria:

* Known case of cardiopulmonary disease, BP \> 180/100 mmHg twice in 24 hours
* Known case of neurological disease other than stroke, Known case of orthopedic disease i-e funnel chest, rib fractures or any other orthopedic deformity
* Medication that would influence metabolic or cardiorespiratory responses to exercise Impaired level of consciousness, Evidence of gross cognitive impairment.

Primary outcomes:
measure: pulmonary function
timeFrame: 4 weeks
measure: Trunk Control
timeFrame: 4weeks
measure: Functional Capacity
timeFrame: 4weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Peshawar
country: Pakistan
facility: Northwest General Hospital, Peshawar;
state: Punjab
Study officials:
affiliation: Riphah International University
name: Maria Razzaq, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01817101: Dietary Supplement for the Prevention of Cognitive Decline in a Very Elderly Population.
Official title: Field Trial With Omega-3 Fatty Acid Supplementation for the Prevention of Cognitive Decline in a Very Elderly Population
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Mild Cognitive Impairment
Lead sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Sponsor class: OTHER
First posted: 2013-03-22
Enrollment: 170
Sex: ALL
Minimum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine whether an omega-3 fatty acid supplementation is effective in the prevention of progressive cognitive decline in elderly people aged 75 years or older.

Detailed description: Participants are residents at three nursing homes in Pamplona (Spain). We assumed that 20% of elderly people have a cognitive decline and we estimated a 5% of cognitive decline in the intervention group. Sample size estimated was 85 participants for each arm, assuming two groups with an alpha of 0.05, 80% power and accounting for 10% of participants lost to follow-up.

Repeated measures ANOVA, Cox regression and multiple linear regression analysis will be used for the statistical analysis of data.

Eligibility criteria: Inclusion Criteria:

* Elderly people aged 75 years or older
* Global Deterioration Scale \< 4
* Capacity to complete the tests

Exclusion Criteria:

* Neurological, physical or psychiatry conditions, obtained from the medical history, that may have an influence on the cognitive function.
* Dementia
* History of epilepsy, convulsions

Primary outcomes:
measure: Mini Mental State Examination
timeFrame: Six months / one year
Secondary outcomes:
measure: Short Portable Mental Status Questionnaire (SPMSQ)
timeFrame: One year
measure: Verbal fluency test
timeFrame: One year
measure: Clock-drawing test
timeFrame: One year
Other outcomes:
Locations:
city: Pamplona
country: Spain
facility: Amma Argaray
state: Navarra
city: Pamplona
country: Spain
facility: AMMA Mutilva
state: Navarra
city: Pamplona
country: Spain
facility: AMMA Oblatas
state: Navarra
Study officials:
affiliation: Clinica Universidad de Navarra
name: Joaquin Baleztena, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00541801: Acoustic Cardiographic Assessment of Heart Function in Comparison to Doppler-echocardiography
Official title: Acoustic Cardiographic Assessment of Heart Function in Comparison to Doppler-echocardiography in Patients With Cytostatic Therapies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Failure, Congestive
Antineoplastic Agents
Lead sponsor: Luzerner Kantonsspital
Sponsor class: OTHER
Collaborators: name: Inovise Medical
First posted: 2007-10-10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: In this study, the investigators sought to determine whether an acoustic cardiographic assessment of heart function is equivalent to Doppler-echocardiography in patients who are treated with cardio-toxic cytostatic agents.

Detailed description: Patients receiving cardio-toxic cytostatic agents are examined by Doppler-echocardiography and acoustic cardiography before, during, and after the cytostatic treatment. Doppler-echocardiography measures ejection fraction, TDI, speckle tracking, and further parameters. Acoustic cardiography (Audicor, Inovise Medical Inc., Portland, USA) simultaneously integrates heart sounds and single-channel electrocardiography input to generate multiple parameters that correlate to established hemodynamic measures. Heart function as assessed by Doppler-echocardiography is then compared to the heart function as assessed by Audicor ECG.

Eligibility criteria: Inclusion Criteria:

* Patients with malignant disease with scheduled anthracycline and trastuzumab therapy

Primary outcomes:
measure: Changes of echocardiographic parameters and changes of electromechanical activation time (EMAT)and development of third heart sound as indicators of congestive heart failure
timeFrame: Repeated measurements over a year
Secondary outcomes:
measure: Development of clinically overt congestive heart failure
timeFrame: One year
Other outcomes:
Locations:
city: Luzern
country: Switzerland
facility: Kantonsspital Luzern, Department of Cardiology
Study officials:
affiliation: Luzerner Kantonsspital
name: Paul Erne, MD
role: STUDY_CHAIR
References:
Clinical trial NCT04076501: Effect of Short-term Oxygen During CPET in GUCH
Official title: Effect of Short-term Ambulatory Oxygen Therapy on Cardiopulmonary Exercise Capacity (CPET) in Patients With Grown-up Congenital Heart Disease (GUCH)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Grown-up Congenital Heart Disease (GUCH)
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2019-09-03
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: In a randomized, sham-controlled crossover trial the investigators will test whether supplemental oxygen given during cardiopulmonary exercise testing will improve exercise performance and physiological parameters in patients with grown-up congenital heart disease.


Eligibility criteria: Inclusion Criteria:

* GUCH, stable medication for at least 4 weeks.

Exclusion Criteria:

* instable status, pregnancy, clinically relevant concomitant diseases, inability to follow the study procedures

Primary outcomes:
measure: Work Rate (Watt)
timeFrame: 1 day
measure: Endurance Time (s) Endurance Time (s) Endurance Time (s)
timeFrame: 1 day
Secondary outcomes:
measure: Peak Oxygen uptake
timeFrame: 1 day
measure: Respiratory Exchange ratio
timeFrame: 1 day
measure: Changes in arterial blood parameters
timeFrame: 1 day
measure: muscle tissue oxygen
timeFrame: 1 day
measure: cerebral tissue oxygen
timeFrame: 1 day
Other outcomes:
Locations:
city: Zürich
country: Switzerland
facility: University Hospital Zurich, Division of Pneumology
Study officials:
References:
Clinical trial NCT03839901: Rehabilitation Programmes for Scapholunate Instability
Official title: A Pilot Study to Investigate Two Different Physiotherapy Rehabilitation Programmes, to Treat the Conservatively Managed Scapholunate Instability.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Wrist Strain
Wrist Sprain
Scaphoid-Lunate Instability
Keywords: Scaphoid-Lunate
instability
wrist
Lead sponsor: University of Bradford
Sponsor class: OTHER
Collaborators: name: Bradford Teaching Hospitals NHS Foundation Trust
First posted: 2019-02-15
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Two different exercises approaches were tested in patients with Scapho-Lunate (SL) instability; one to strengthen the tendons in static positions and the other to strengthen the tendons whilst the wrist is moving.

Detailed description: Scapho-Lunate (SL) instability is the most common form of wrist instability, but is complex to diagnose and is often missed entirely. The natural progression of SL instability has been suggested to lead to osteoarthritis. The management of SL instability can be broadly divided into conservative and surgical, with the former being the first option taken by most medical professionals, which primarily involves physiotherapy. The evidence base for physiotherapy management of SL instability is limited; however cadaver research has identified loading some of the wrist tendons may stabilise the scaphoid and lunate.There is currently no research as to whether this clinically makes any difference to the patients symptoms, or how to do it. This research therefore aimed to test the protocol and methods, and act as a platform for larger studies, to investigate this.

Two different exercises approaches were tested; one to strengthen the tendons in static positions and the other to strengthen the tendons whilst the wrist is moving.

Eligibility criteria: Inclusion Criteria:

* Ages eighteen to sixty,
* wrist pain,
* confirmed scapholunate ligament disruption on MRA or XR (partial or full),
* referred from orthopaedic wrist specialist,
* for conservative management,
* consent to trial.

Exclusion Criteria:

* Under eighteen or over sixty years,
* previous fracture,
* degenerative changes in the wrist,
* previous surgery,
* complex regional pain syndrome or diagnosis of rheumatological conditions,
* no wrist injection in preceding twelve months or other wrist conditions.

Primary outcomes:
measure: Grip strength using E-link dynamometer
timeFrame: assessed at 0, 4 and 8 weeks
Secondary outcomes:
measure: numerical rating scale
timeFrame: assessed at 0, 4 and 8 weeks
measure: Patient Rated Wrist Evaluation
timeFrame: assessed at 0, 4 and 8 weeks
Other outcomes:
Locations:
city: Bradford
country: United Kingdom
facility: Bradford Royal Infirmary
state: West Yorkshire
Study officials:
References:
Clinical trial NCT03526601: Screening Of Adult urBan pOpulation To diAgnose Heart Failure
Official title: Screening Of Adult urBan pOpulation To diAgnose Heart Failure
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Heart Failure
Keywords: heart failure
prevalence
Lead sponsor: General Hospital Murska Sobota
Sponsor class: OTHER
Collaborators: name: Roche Pharma AG
name: Slovenian Research Agency
name: Murska Sobota Municipiality
name: Community Health Center Murska Sobota
First posted: 2018-05-16
Enrollment: 2861
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: 60% of Murska Sobota residents aged 55 years or more

Brief summary: Screening Of adult urBan pOpulation To diAgnose Heart Failure (SOBOTA-HF) is a cross-sectional prevalence study in a representative sample of Murska Sobota residents aged 55 years or more. Individuals will be invited to participate in a screening with NT-proBNP. All subjects with NT-proBNP ≥ 125 pg/mL will be invited for a diagnostic visit that will include history and physical examination, electrocardiogram, echocardiography, ankle brachial index, pulmonary function tests, body composition measurement, physical performance tests and questionnaires. To validate the screening procedure, a control group (NT-proBNP \< 125 pg/mL) will undergo same diagnostic evaluation. An external center will validate echodardiography exams and the HF diagnosis will be adjudicated within an independent HF expert panel. Overall and age specific HF prevalence will be calculated in individuals ≥ 55 years and extrapolated to the whole population.


Eligibility criteria: Inclusion Criteria:

* age \>55
* living in Murska Sobota
* part of representative sample as selected by Statistical Office of the Republic of Slovenia

Exclusion Criteria:

NONE.

Primary outcomes:
measure: heart failure diagnosis as per 2016 ESC guidelines
timeFrame: at diagnostic visit
Secondary outcomes:
Other outcomes:
Locations:
city: Murska Sobota
country: Slovenia
facility: General Hospital Murska Sobota
Study officials:
affiliation: General Hospital Murska Sobota
name: Mitja Lainscak, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05411601: Numerical Standard of Anthropomorphicity of Prosthetic Feet for Improvement of Amputee Performance
Official title: Numerical Standard of Anthropomorphicity of Prosthetic Feet for Improvement of Amputee Performance
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Testing of Methodology of Attachment of External Foot Prothesis Based on Anthropomorphism Criteria
Lead sponsor: PolyOrth International
Sponsor class: INDUSTRY
First posted: 2022-06-09
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects 18-60 years old that underwent unilateral lower transtibial amputation

Brief summary: The study concerns the testing of methodology of attachment of external foot prothesis based on anthropomorphism criteria


Eligibility criteria: Inclusion Criteria:

* Unilateral lower transtibial amputation
* Prosthetic user with socket type attachment (Cohort 1) or with direct skeletal attachment (Cohort 2) and be able to walk 50 meters independently,
* Between 18-60 years of age,
* Able to follow instructions,
* Able to provide consent.

Exclusion Criteria:

* problems on the residuum,
* Non-prosthetic user,
* Bilateral amputation,
* Self-reported pain levels greater than 4 out of 10 at study outset,
* Experienced a fall within the last 8 weeks before assessment,
* Mental illness or intellectual impairment compromising participant's ability to give informed consent,
* Injuries involving contralateral (intact) limb,
* Major uncorrected visual deficit,
* History of epilepsy or recurrent dizziness,

Primary outcomes:
measure: Stiffness and the index of anthropomorphicity IAm
timeFrame: 30 days
measure: IAb of the selected prosthetic feet
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01263301: Differential Diagnosis for the Causes of Subclavian Steal for Patients With Vascular Access in the Forearm
Official title: Differential Diagnosis for the Causes of Subclavian Steal for Patients With Vascular Access in the Forearm
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Subclavian Steal
Keywords: subclavian steal
carotid duplex
subclavian stenosis
hemodialysis with vascular access in the upper limbs
the focus of this study is to see if duplex can be used as an tool to differentiate the different causes of subclavian steal syndromes
Lead sponsor: Mennonite Christian Hospital
Sponsor class: OTHER
First posted: 2010-12-20
Enrollment: 16
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Subclavian steal phenomenon is normally observed in patients with stenosis of subclavian artery proximal to orifice of vertebral artery(V0). However, uremic patients undergoing hemodialysis using vascular access in the arm or forearm may also develop dialysis associated steal syndrome(DASS).For patients with symptomatic subclavian steal phenomenon, the treatment for these two groups is different. The investigators want to see if the investigators can use noninvasive duplex examination instead of invasive conventional angiography to do the differential diagnosis.

Detailed description: Carotid duplex is widely used for diagnosis of subclavian steal syndrome. We have a patient who suffered from acute brain stem stroke after receiving hemodialysis for months. He has DM related uremia and the vascular access is in the forearm. Subclavian steal was found on duplex in the same arm for hemodialysis. We used standard cuff test for diagnosis of subclavian steal by carotid duplex examination. Accidentally, we found the flow of subclavian artery was back to normal when the cuff is on that stops the flow. We want to see if this phenomenon can be used to serve as a differential diagnostic tool for differentiation of subclavian steal caused by stenosis of subclavian artery or due to DASS.

Eligibility criteria: Inclusion Criteria:

* patients who revealed subclavian steal in the duplex study

Exclusion Criteria:

* patients who has vascular access in the arm instead of the forearm

Primary outcomes:
measure: Change of Subclavian Flow to Normal Flow Pattern During Cuff Test
timeFrame: two years
measure: no Change of Subclavian Arterial Flow During Cuff Test
timeFrame: one year
measure: Change of Vertebral Flow to Normal Flow Pattern During Cuff Test
timeFrame: two year
measure: no Change of Vertebral Arterial Flow During Cuff Test
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Hua Lien
country: Taiwan
facility: Mennonite Christial Hospital
Study officials:
affiliation: Mennonite Christian Hospital
name: lingchih wu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00383201: Effect of Multi-Purpose Solutions on Ex-Vivo Wetting Angles
Official title: Long-Term Effect of Multi-Purpose Solutions on Ex-Vivo Wetting Angles of Soft Contact Lenses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Contact Lens Care
Keywords: Contact Lens Care
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2006-10-02
Enrollment: 80
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To clinically evaluate the effect of a new multi-purpose disinfecting solution compared to a marketed multi-purpose solution on wettability of soft contact lenses worn for 30 days.


Eligibility criteria: * Successful daily wear of FDA Group I or IV soft contact lenses for at least one week.
* Vision correctable to 20/30.
* Normal eyes - no current ocular abnormalities that prevent successful contact lens wear.
* No corneal surgery within the past 12 months.
* No systemic disease that affects that eye or that could be worsened by the use of contact lenses or solutions.
* No over-the-counter or prescription ocular medication.

Primary outcomes:
measure: Efficacy:
measure: Contact lens wetting angle measured ex-vivo
measure: Safety:
measure: Slit-lamp Findings: Eyelids and Conjunctiva; Cornea; Iris, Anterior Chamber
measure: Visual Acuity (Snellen)
measure: Adverse Events
Secondary outcomes:
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: Fort Worth Site
state: Texas
Study officials:
affiliation: Alcon Research
name: Leslie Napier
role: STUDY_DIRECTOR
References:
Clinical trial NCT02889601: DAPHNE Scale Validation in Frontotemporal Lobar Degeneration
Official title: Psycho-behavioral Disorders in Frontotemporal Lobar Degeneration: Validation of a Quantification and Follow-up Scale
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Frontotemporal Lobar Degeneration
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
First posted: 2016-09-05
Enrollment: 89
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Frontotemporal lobar degeneration according Neary (1998) and Raskowsky (2011) diagnostic criteria.

Brief summary: Psycho-behavioral disorders assessment is crucial for the diagnosis and follow-up of patients with frontotemporal degeneration (FTD). DAPHNE scientific staff have therefore developed a quantification and follow-up scale specifically dedicated to patients with FTD in current clinical practice. This scale is called DAPHNE to Disinhibition, Apathy, Perseveration, Hyper orality, Negligence and loss of Empathy.

Detailed description: Psycho-behavioral disorders assessment is crucial for the diagnosis and follow-up of patients with frontotemporal degeneration (FTD). DAPHNE scientific staff have therefore developed a quantification and follow-up scale specifically dedicated to patients with FTD in current clinical practice. This scale is called DAPHNE to Disinhibition, Apathy, Perseveration, Hyperorality, Negligence and loss of Empathy. This study aims to validate this scale. This validation will include methodological steps required to develop a new clinical tool, by studying internal consistency, loyalty, and concurrent validity in comparison with validated existing tools. Complementarily, sensitivity and specificity will be assessed via a control population including patients with Alzheimer's disease, , progressive supranuclear palsy and bipolar disorder with cognitive disorders.

Eligibility criteria: Inclusion Criteria:

Group 1:

1. Patients with FTD according Neary (1998) and Raskowsky (2011) diagnostic criteria.
2. Mini-Mental State Examination ≥ 18
3. Consent

Group 2 Control:

1. Patients with Alzheimer's disease (MacKahn, 2011), patients with supranuclear palsy (Litvan, 1996) and patients with bipolar disorder with cognitive disorders.

   criteria.
2. Mini-Mental State Examination ≥ 18
3. Consent

Exclusion Criteria:

* Minor patient

Primary outcomes:
measure: Internal validation of DAPHNE Score
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Nantes
country: France
facility: Nantes University Hospital
Study officials:
References: